Personalized vaccine for triple negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a personalized vaccine made from your tumor's unique markers (neoantigens) to help your immune system fight triple negative breast cancer. You must have already completed standard treatments like chemotherapy, radiation, or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with triple negative breast cancer
- You have already had chemotherapy, radiation, or surgery for your cancer
- Your tumor's unique markers (neoantigens) were successfully identified and made into a vaccine
- You have good veins for IV access and weigh at least 110 pounds (50 kg)
- You are generally active and able to care for yourself (Karnofsky score above 70%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
This trial tests a personalized cancer vaccine designed to train your immune system to fight triple negative breast cancer. It is for people who are already receiving or about to receive the standard KEYNOTE 522 treatment, and the vaccine is given after a few months of that treatment.
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.